WHO recommendations for influenza virus vaccine composition for the 2018 southern hemisphere influenza season
The World Health Organization (WHO) has recommended the composition of the trivalent influenza vaccine for the southern hemisphere winter 2018 influenza season in a report published 28 September 2017.
Influenza season 2010/11 – Norway’s risk assessment and revisited vaccine recommendationsArchived
An important conclusion from this process is that the current situation, with B viruses dominating (80%), is likely to continue through the season.
ECDC – VAESCO investigation into narcolepsyArchived
This initiative was taken following the indication of a potential association between the 2009 pandemic influenza A(H1N1) monvalent vaccine and the occurrence of narcolepsy following reports, especially in children from Finland and Sweden.
Influenza vaccine: selection of strains to be included in the seasonal vaccine for the Northern Hemisphere 2011-2012 – Early indications of seasonal vaccine effectiveness in EuropeArchived
This recommendation for the Northern Hemisphere is the same as for the season 2010-2011 and for the Southern Hemisphere season.
Reports of cases of narcolepsy and cataplexy in children and adolescents in Finland, Iceland, and SwedenArchived
In February 2011, ECDC published a report concerning a rise in narcolepsy in children and adolescents in some northern countries.
Swedish MPA publishes interim results of a cohort study assessing the risk of narcolepsy after vaccination with Pandemic influenza vaccine Pandemrix®Archived
A four-fold increased incidence of narcolepsy in vaccinated children/adolescents compared to unvaccinated children was observed in this register-based cohort study.
Narcolepsy following pandemic influenza A H1N1 2009 vaccination - ECDC update: the European Medicines Agency interim measures for PandemrixArchived
In late March, 2011 ECDC reported that the Swedish Medical Product Agency published preliminary results from an on-going cohort study involving 5.3 million people, where 67% of children and adolescents and 51.0% of adults were vaccinated with Pandemrix.
European Medicines Agency (EMA) 2009 Influenza Pandemic EvaluationArchived
The European Medicines Agency (EMA) was key in the Europe during the 2009 pandemic concerning the authorisation and the benefit – risk assessment of the novel pandemic vaccines.
Case inventory study from Sweden concerning association of Pandemrix vaccination and reports of narcolepsy with cataplexy in children and adolescentsArchived
ECDC has previously summarised information concerning the appearance of narcolepsy following the use of a specific pandemic vaccine (Pandemrix®) in children and adolescents in three European Countries.
Recommendation by the European Medicines Agency concerning Pandemrix vaccination and reports of narcolepsy in children and adolescentsArchived
EMA recommends restricting use in persons under 20 years of age Pandemrix to be used only in the absence of seasonal trivalent influenza vaccines, following link to very rare cases of narcolepsy in young people. Overall benefit-risk remains positive.